RecruitingPhase 2NCT06460038

Tenapanor in Synucleinopathy-Related Constipation

Efficacy and Safety of Tenapanor in Synucleinopathy-Related Constipation


Sponsor

Cedar Valley Digestive Health Center

Enrollment

30 participants

Start Date

Jan 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation


Eligibility

Min Age: 50 YearsMax Age: 89 Years

Plain Language Summary

Simplified for easier understanding

This study investigates whether tenapanor, a medication currently used for irritable bowel syndrome, can help relieve constipation in people with synucleinopathy-related conditions — such as Parkinson's disease or Lewy body dementia — where constipation is a common and distressing symptom. **You may be eligible if...** - You have a synucleinopathy such as Parkinson's disease or Lewy body disease - You experience constipation related to your condition - Your doctor determines you meet the study's medical requirements **You may NOT be eligible if...** - The specific exclusion criteria have not been published for this trial at this time - You should confirm eligibility details directly with your care team Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTenapanor

Inhibitor of NHE3

DRUGPlacebo

Placebo drug


Locations(1)

Cedar Valley Digestive Health Center

Waterloo, Iowa, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06460038


Related Trials